IEX has had a strong week — up nearly 7% to $217.34 — while short sellers quietly step back, and options traders shift toward a notably bullish tilt ahead of a May 6 earnings call.
The most striking feature of this week's setup is the divergence between the price action and where shorts were sitting just two weeks ago. Short interest peaked near 3.2% of the free float in early April, when the tariff-driven macro sell-off hit industrial names hardest. It has since pulled back to 2.75%, a steady five-week retreat that tracks almost exactly with the stock's recovery from its April lows. Short sellers appear to be reducing exposure into strength rather than pressing new bets.
The lending market reinforces that read. Borrow availability is very loose — the borrow cost is just 0.42% annualised, close to its cheapest level of the past six weeks, and availability is far from constrained. There is no squeeze dynamic at play here. The options market tells the same story from a different angle: the put/call ratio has dropped to 0.62, well below its 20-day average of 0.92. That is nearly a full standard deviation below the recent norm, reflecting a genuine rotation toward calls as the stock has rallied. The contrast with mid-April, when the PCR ran above 1.33 for several consecutive sessions, is stark.
The Street broadly backs the recovery. Most analysts carry Buy or Outperform ratings, with a consensus price target of $231.57 — roughly 6.5% above the current price. The most recent move came from Stifel on April 14, where analyst Nathan Jones trimmed his target slightly from $244 to $241 while keeping a Buy. BMO Capital initiated at Market Perform with a $214 target in late March, providing the main counterpoint. Bulls point to 7% order growth across data centres, municipal water, and semiconductor MRO, plus 5% organic revenue growth that beat prior estimates in FMT and HST. Bears flag a 2.0x gross debt/EBITDA ratio and mixed organic sales trends across segments as a ceiling on re-rating. The PE now trades around 25x, up roughly 2.7 points over the past month as the stock has recovered, while EV/EBITDA has expanded to 17.7x.
On EPS momentum the picture is less compelling. Factor scores rank IEX at only the 38th percentile for 30-day EPS momentum and 41st for 90-day, suggesting estimate revisions have not kept pace with the share price. The forward EPS growth score is the clear standout at the 87th percentile — the Street sees earnings growing, even if near-term revision momentum has been muted.
The notable institutional flow is PRIMECAP, which added nearly 1.5 million shares in its most recent filing — a meaningful addition. Dodge & Cox and Millennium also both added substantially in the prior quarter. That kind of accumulation from active managers alongside the price recovery adds texture to the bull case, though the buy-high-add-more pattern means those holders are now sitting on positions at meaningfully higher cost bases.
Peers have had a rougher week. IR fell 7.5% on the week and GGG dropped 7.0%, while IEX gained 6.7%. The outperformance is notable given the shared macro exposure. What to watch is whether the May 6 print — the next confirmed event — validates the order-growth story that the bull case and recent price action are already discounting.
See the live data behind this article on ORTEX.
Open IEX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
